Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 52-year-old male who underwent a deceased-donor renal transplantation 8 months ago is evaluated in the inpatient medical ward for a 4-day history of fever, dry cough, and right-sided pleuritic chest pain. His current medications include tacrolimus, mycophenolate mofetil, and prednisone. Temperature is 38.6°C (101.5°F), blood pressure is 132/82 mmHg, pulse is 108/min, and respirations are 20/min. Oxygen saturation is 93% on room air. Laboratory studies reveal a serum creatinine of 1.4 mg/dL (baseline 1.3 mg/dL). A non-contrast CT scan of the chest demonstrates a nodular consolidation with a surrounding ground-glass opacity (halo sign) in the right upper lobe. Bronchoscopy with bronchoalveolar lavage is performed, and galactomannan antigen testing is markedly positive. The infectious disease service recommends initiating intravenous voriconazole. Which of the following is the most appropriate pharmacologic intervention regarding this patient's current medication regimen?

  1. Decrease the tacrolimus dose and monitor serum trough levelsCevap
  2. B
    Increase the tacrolimus dose to compensate for enhanced hepatic metabolism
  3. C
    Substitute fluconazole for the recommended antifungal to avoid drug interactions
  4. D
    Switch tacrolimus to cyclosporine to bypass cytochrome P450 interference
  5. E
    Temporarily discontinue all immunosuppressive therapy until the infection resolves

Cevap

Decrease the tacrolimus dose and monitor serum trough levels
The correct intervention is to decrease the tacrolimus dose and closely monitor serum trough levels. Voriconazole, the first-line pharmacotherapy for invasive pulmonary aspergillosis, is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor that relies heavily on CYP3A4 for its metabolism and clearance. Coadministration of these two agents without adjusting the baseline immunosuppressive regimen will rapidly lead to supratherapeutic tacrolimus levels. This significantly increases the risk of severe side effects, most notably acute nephrotoxicity, neurotoxicity (such as tremors or seizures), and over-immunosuppression. Standard clinical guidelines mandate reducing the tacrolimus dose—often by approximately one-third to one-half—when initiating voriconazole, followed by meticulous therapeutic drug monitoring.

Adım Adım Çözüm

1
Identify the primary diagnosis and confirm the necessity of the recommended treatment.
The patient's clinical presentation, halo sign on CT, and markedly positive galactomannan antigen confirm invasive pulmonary aspergillosis, which necessitates treatment with voriconazole.
Establishing the correct therapeutic agent is required to evaluate potential drug-drug interactions with the patient's baseline regimen.
2
Analyze the pharmacokinetic properties of both the baseline immunosuppressants and the newly prescribed antifungal.
Voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor heavily metabolized by CYP3A4.
Recognizing this specific enzyme interaction is critical to preventing iatrogenic toxicity.
3
Determine the appropriate dose adjustment strategy to mitigate the interaction.
The tacrolimus dose must be empirically reduced (typically by one-third to one-half) upon starting voriconazole, accompanied by close therapeutic drug monitoring.
Proactive dose reduction prevents supratherapeutic tacrolimus concentrations, which would otherwise lead to severe nephrotoxicity and neurotoxicity.

Anahtar Kavram

Initiation of voriconazole, a potent CYP3A4 inhibitor, in a patient taking tacrolimus requires a pre-emptive reduction in the tacrolimus dose and close therapeutic drug monitoring to prevent severe calcineurin inhibitor toxicity.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru